Honeybees are essential for food production, resilient agriculture, and our ecosystem. At the same time, the parasitic Varroa mite threatens our honeybees. Every colony is now infected, and if left untreated, colonies collapse within two years. Options for protecting bees from Varroa mites are limited, unreliable, and outdated.
VAROLIS aims to obtain approval for our novel active ingredient, LIMITEX, as a veterinary medicinal product. LIMITEX is highly effective and easy to use. It is well tolerated by bees and leaves no residues in bee products. The data has been extensively tested and validated in field trials under beekeeping conditions. VAROLIS has freedom to operate and licenses for all necessary patents.
The market size exceeds €2 billion annually, production costs are low, and the product is highly profitable. Based on conservative assumptions, VAROLIS will achieve a return on investment within just two years of market launch. Our preclinical data package and the preliminary work on quality and safety for LIMITEX reduce the risk for the regulatory approval process.
Our team is experienced as entrepreneurs, scientists, beekeepers, and in drug development. We are also supported by a diverse team of consultants and experts. In addition to the positive impact on our environment, our B2B and B2C business models open up promising economic opportunities.
To achieve our goal, we now need financial support from strategic partners who want to accompany us on our journey towards improved bee protection, resilient agriculture, food security, biodiversity and healthy ecosystems.
Honey Bees are of vital importance for food safety, resilient agriculture and balanced ecosystems. At the same time the Honey Bee is critically endangered by the parasitic Varroa mite. Meanwhile every honey bee colony is infested and untreated colonies collapse within 2 years. The options to control the deadly mite are limited, outdated and widely insufficient. VAROLIS has set out to obtain regulatory approval for our new drug, LIMITEX, as veterinary medicine for honey bees. LIMITEX is highly efficient and easy to apply. It is well tolerated by bees and does not leave residues in bee products. Our data were obtained and validated in scientific field studies under good bee keeping practice. VAROLIS has Freedom to Operate and Licenses to all relevant IP. The market size exceeds €2Bn, annually, the Costs of Goods are low and the product highly profitable. Even based on conservative assumptions concerning market share, our financial plan indicates a return of investment 2 years after product launch. Our preclinical data package and our preparatory work regarding quality and safety of our product minimizes the risk for the regulatory approval of LIMITEX as veterinary drug. Our team combines expertise in the field of entrepreneurship, research and science, bee keeping and apidology, as well as drug discovery and development. In addition, a team of consultants covers a wide variety of experience and expertise. Thus, besides positive impacts on our environment, our B2B and B2C business model around our product LIMITEX also opens promising economic opportunities. To achieve our goal we now seek funding by strategic partners, who want to accompany VAROLIS on its way to improved Honey Bee health, resilient agriculture, food safety and balanced ecosystems.
